Can B Corp (CANB)

[skyhawk66]

Misleading, again. CANB Accumulation continues, Daily/Weekly/Monthly. Even today 500 shares traded on a negative day. With Record Earnings easy to see why shareholders are holding on to their discounted shares.
After 4 years, negative opinion holds nothing believable.

Nasdaq Cometh

[Penny Masters]

Wonder what sector CANB will try next time? They are pretty much done here and will need to re-invent themselves in something else. My guess is mining or crypto crap.

What is everyone else guess for next sector?

Peace out

[skyhawk66]

Agree, CANB Green Day Again, Up almost
7%.
EOD Accumulation Continues.

Nasdaq Cometh

[badguy3101]

Calm cool and collected

NASDAQ

CANB




The Badguy

[waterchaser]

Where does one find "misleading information" about CANB?
I haven't seen any.

BTW, what's the pre-reverse split value of CANB today?
I don't have the data readily available.

Thanks.

[skyhawk66]

Misleading Information seems to be causing a Positive Effect on CANB…
Up Again Today, Over 13%

Goes to show, at this Oversold Level…Smart Money Accumulation Continues Daily/Weekly and Monthly.

Can’t wait to see the Next Impressive Quarter!

Nasdaq Cometh

[waterchaser]

I'm seeing zero volume for CANB.
Is this thing finally dead?

[waterchaser]

And, the pre-split value here is?

[skyhawk66]

Another Green Close with Continued EOD Accumulation at these Discounted Levels. Wait a minute wasn’t CANB suppose to go under 4 years ago??
So much for Misleading Rumors,
Lol!

Nasdaq Cometh

[waterchaser]

Wow, almost made it to two bucks today.

What’s that in pre-split numbers?

[Penny Masters]

CANB LOOK OUT BELOWWWW. Under 2.00 and ship is going down for the final time.. Help do another RS fast. LOL

Take care and better luck on your next sleek pic as all know what these were. Some should be in jail for what they did.

Peace out

[Penny Masters]

Obvious CANB is over and simply awaits the house of cards to finally fall.

Nasty what was done and how these OTC cesspool plays works. Maybe a 3rd RS will help. LOL

Peace out

[waterchaser]

What’s the pre-split equivalent of CANB today?

Odds are 1,000 to 1 that no promo wants that number advertised.

[skyhawk66]

Misleading, again. CANB Accumulation continues, Daily/Weekly/Monthly. With Record Earnings easy to see why.
After 4 years, negative opinion holds nothing believable.

Nasdaq Cometh

[Penny Masters]

No one is buying CANB any longer. Slow bleed now till the house of cards falls. Nasty what was done, as it was really sleek what they did. Some should end up in jail for the way they pumped this and other train wrecks.

Peace out

[skyhawk66]

Congrats to the New CANB Shareholders as Accumulating Continues Daily/Weekly/Monthly. Negative Opinions are lost in the wind, especially 4 years later.
FACTS:
E HIGHEST QUARTERLY REVENUE IN COMPANY HISTORY, Very Impressive Indeed:

Can B Corp. Reports First Quarter Revenue Growth of 606% to $1.9 Million, the Highest Quarterly Revenue in Company History
May 18 2022 - 07:26AM
InvestorsHub NewsWire
Alert
Print
Share On Facebook
Strengthened Balance Sheet with Increases to $17.0 Million in Total Assets and $6.2 Million in Stockholders Equity

HICKSVILLE, NY -- May 18, 2022 -- InvestorsHub NewsWire -- Can B Corp. (OTCQB: CANB) (“Can B'' or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company's financial results for the first quarter ended March 31, 2022.

Key Financial Highlights for Q1 2022

Revenue increased 606% to $1.9 million
Gross profit increased 291% to $0.7 million
Adjusted EBITDA loss decreased 30% to $0.9 million
Total assets increased to $17.0 million
Total stockholders’ equity increased to $6.2 million
Key Business Highlights for Q1 2022

Solidified and integrated vertical processing capabilities from recent acquisitions
Advanced build-out of first CBD lounge in Miami, Florida
Continuing path for potential NASDAQ up-listing
Management Commentary

Marco Alfonsi, Can B’s Chief Executive Officer, stated, “We are extremely pleased with our tremendous quarterly results, having achieved the highest quarterly revenue in our company history. We generated the $1.9 million in quarterly revenue while reducing our cash burn as demonstrated by the decrease in adjusted EBITDA to $0.9 million. The strategic moves we have made over the past several months have completed our vertical processing capabilities and put us in great position to accelerate our revenue growth and strengthen our balance sheet. This quarter’s results prove our plans are working as our team continues its hard at work integrating and ramping up the various operations to continue this momentum into the future.”

Alfonsi concluded, “Can B is now a full-service hemp-derived cannabinoid company that can facilitate servicing the large box types as well as the boutique vape and smoke store. Our dramatic revenue improvements, coupled with our acquisitions and asset base increases, position us solidly to continue our application process for a NASDA up listing.”

Vertical Processing Capabilities

Secured hemp biomass and winterized crude to create over 13,000 Liters (1 Liter = 1.05 Quarts) of isomers, including Delta-8, with a potential wholesale value exceeding $10 million at today's market price. Can B's late 2021 acquired facilities in Colorado will receive harvested hemp biomass and convert it to winterized crude. These same facilities will then process it to distillate, then to isolate which will be shipped to Company-owned facilities in Florida and Tennessee to produce Delta-8 or other isomers, or to its manufacturing facility in Lacey, Washington for its line of CBD tinctures, salves, gels, and drops. This processing is expected to take 5-6 months to produce 13,000 liters of Delta-8 and other isomers with potential revenue of $10 million.

300,000 Square Foot Facility in McMinnville, Tennessee
Acquisition of Assets from TWS Pharma included leases on a total of 15,000 square foot of facilities located in Mead and Ft. Morgan Colorado.
Acquisition of Assets from Music City Botanicals added additional volume in extraction, isomer lab production, and R&D into the evolving isomer market with such products as Delta-10, CBG, CBN, and CBDA.
Financial Results for the Three Months Ended March 31, 2022:

Revenue: For the three months ended March 31, 2022, revenue was $1.9 million, an increase of $1.6 million, or 606%, compared with $0.3 million for the same period last year. The increase is due to the wind-down of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound device associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase in sales compared to 2021 of $0.6 million.
Gross Profit: For the three months ended March 31, 2022, gross profit was $0.7 million, an increase of $0.4 million, or 291%, compared with $0.2 million for the same period last year. The resulting gross margin was 36.0%, compared with 75.0% for the same period last year.
Total Operating Expenses: For the three months ended March 31, 2022, total operating expenses were $3.9 million, an increase of $1.8 million, or 91%, compared with $2.0 million for the same period last year, as a direct result of professional fees and other accounting and legal fees related to the Company’s registration statement S-1 filing efforts.
Of note, $2.3 million of the Company's operating expenses for the three months ended March 31, 2022, were non-cash expenses, including depreciation, amortization, and stock-based compensation, compared to $0.5 million for the same period last year.

Operating Loss: For the three months ended March 31, 2022, operating loss was $3.2 million, an increase of $1.4 million, compared with an operating loss of $1.8 million for the same period last year.
Adjusted EBITDA Loss: For the three months ended March 31, 2022, Adjusted EBITDA loss was $0.9 million, a decrease of $0.4 million, or 30%, compared with an Adjusted EBITDA loss of $1.3 million for the same period last year, after deducting non-cash and one-time expenses.
Net Loss: For the three months ended March 31, 2022, net loss was $3.5 million, an increase of $1.3 million, or 60%, compared with $2.2 million for the same period last year. The EPS loss per share for the three months ended March 31, 2022, was ($1.10), compared to ($3.58) for the same period last year.
About Can B Corp.

Can B Corp. (OTCQB: CANB) is a health & wellness company providing the highest quality hemp-derived cannabinoid products, including under its own brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil, and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B Corp. operates R&D and production facilities in Lacey, WA, and Florida. To learn more about Can B Corp. and our comprehensive line of high-quality products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: CanBCorp.com

Twitter @CanBCorp

Instagram @canbcorp

Facebook @ Can B Corp

YouTube

[Penny Masters]

Was sure if CANB went under 3.00 they were finished. Now as 2.00 a[approaches, there is nothing to prop the house of cards up any longer. Bloated salaries, MASSIVE debt and products few know or want.

True share holder value after multi RS's is .0009. WOW that is NASTY as CANB would need to hit 50.00 for many to break even.

Say Goodnight, Gracie.

Peace out

[Penny Masters]

CANB pretty much done as they appear to have little left besides a possible sector change announcement. That would be the last thing that will help them with a final share dump.

Good luck all and sorry for the losses. A few RS's will always kill any company and share holders trust.

Peace out

[Penny Masters]

You understand what the multi RS's did to this CANB train wreck. There is no share holder value and all would need 50.00 to break even.... Period!

There will NEVER EVER be NASDAQ for this shit show.... Period!

It sure was a "sleek scheme" that started this and many should be in jail for what was done.,

Peace out

[skyhawk66]

Completely Misleading…CANB Up 20% Today. End Of Day Accumulation Continues…..Period.

Peace Out

[waterchaser]

CANB swirling the toilet once again today.

[Penny Masters]

Figured once CANB hit 3.00 its was over. Now 2.00 approaching and the real value after all the past RS's is .0009 and not sure how the doors can stay open.

Massive debt, bloated salaries and a product no one seems to know or want. What a train wreck that never stops wrecking.

Good luck all and hope you did not get caught up in these OTC cesspool plays. Who ever was pumping them, they sure were sleek and should go to jail. LOL

Peace out

[Penny Masters]

NEVER EVER NASDAQ for the CANB shit show. Funny the BS they put out and some actually believe it.

You will never see NASDAQ. I am so sure I said I will never post on this board again if that happens.

Peace out

[skyhawk66]

As one can see CANB shares are in Strong Hands. Only 250 shares traded so far on a negative day.

Nasdaq Cometh and No negative Opinion can change that course :)

Peace Out

[Penny Masters]

Wow what is CANB up today? LOL CANB is done and stick a fork in it. They cannot do another RS and no one would touch this trainwreck.

Peace out

[badguy3101]

CANB greatness coming

Patients

NASDAQ




The Badguy

[skyhawk66]

Wow CANB- Up Almost 25% Today! Smart Money Continues to Accumulate weekly and Monthly.,
A No Brainer, Very Smart Purchases at this Discounted Level, Very Smart Indeed.

Nasdaq Cometh

[Penny Masters]

After the few RS's CANB value is .0016. Hope you know there is no coming back from the shit show and what they did to share holders. You will need this to be 50.00 to break even. LOLOLOL

Peace out

[waterchaser]

CANB is swirling the toilet.
Buyer beware.

[skyhawk66]

CANB Continues to Look Greater Every Quarter. The weekly going out of business Opinion has gotten boring 4 Yrs ago. Maybe a new negative approach Opinion might be needed, just saying.

OK, Facts Now for the New Monthly Share Holders******

THE HIGHEST QUARTERLY REVENUE IN COMPANY HISTORY, Very Impressive Indeed:

Can B Corp. Reports First Quarter Revenue Growth of 606% to $1.9 Million, the Highest Quarterly Revenue in Company History
May 18 2022 - 07:26AM
InvestorsHub NewsWire
Alert
Print
Share On Facebook
Strengthened Balance Sheet with Increases to $17.0 Million in Total Assets and $6.2 Million in Stockholders Equity

HICKSVILLE, NY -- May 18, 2022 -- InvestorsHub NewsWire -- Can B Corp. (OTCQB: CANB) (“Can B'' or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company's financial results for the first quarter ended March 31, 2022.

Key Financial Highlights for Q1 2022

Revenue increased 606% to $1.9 million
Gross profit increased 291% to $0.7 million
Adjusted EBITDA loss decreased 30% to $0.9 million
Total assets increased to $17.0 million
Total stockholders’ equity increased to $6.2 million
Key Business Highlights for Q1 2022

Solidified and integrated vertical processing capabilities from recent acquisitions
Advanced build-out of first CBD lounge in Miami, Florida
Continuing path for potential NASDAQ up-listing
Management Commentary

Marco Alfonsi, Can B’s Chief Executive Officer, stated, “We are extremely pleased with our tremendous quarterly results, having achieved the highest quarterly revenue in our company history. We generated the $1.9 million in quarterly revenue while reducing our cash burn as demonstrated by the decrease in adjusted EBITDA to $0.9 million. The strategic moves we have made over the past several months have completed our vertical processing capabilities and put us in great position to accelerate our revenue growth and strengthen our balance sheet. This quarter’s results prove our plans are working as our team continues its hard at work integrating and ramping up the various operations to continue this momentum into the future.”

Alfonsi concluded, “Can B is now a full-service hemp-derived cannabinoid company that can facilitate servicing the large box types as well as the boutique vape and smoke store. Our dramatic revenue improvements, coupled with our acquisitions and asset base increases, position us solidly to continue our application process for a NASDA up listing.”

Vertical Processing Capabilities

Secured hemp biomass and winterized crude to create over 13,000 Liters (1 Liter = 1.05 Quarts) of isomers, including Delta-8, with a potential wholesale value exceeding $10 million at today's market price. Can B's late 2021 acquired facilities in Colorado will receive harvested hemp biomass and convert it to winterized crude. These same facilities will then process it to distillate, then to isolate which will be shipped to Company-owned facilities in Florida and Tennessee to produce Delta-8 or other isomers, or to its manufacturing facility in Lacey, Washington for its line of CBD tinctures, salves, gels, and drops. This processing is expected to take 5-6 months to produce 13,000 liters of Delta-8 and other isomers with potential revenue of $10 million.

300,000 Square Foot Facility in McMinnville, Tennessee
Acquisition of Assets from TWS Pharma included leases on a total of 15,000 square foot of facilities located in Mead and Ft. Morgan Colorado.
Acquisition of Assets from Music City Botanicals added additional volume in extraction, isomer lab production, and R&D into the evolving isomer market with such products as Delta-10, CBG, CBN, and CBDA.
Financial Results for the Three Months Ended March 31, 2022:

Revenue: For the three months ended March 31, 2022, revenue was $1.9 million, an increase of $1.6 million, or 606%, compared with $0.3 million for the same period last year. The increase is due to the wind-down of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound device associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase in sales compared to 2021 of $0.6 million.
Gross Profit: For the three months ended March 31, 2022, gross profit was $0.7 million, an increase of $0.4 million, or 291%, compared with $0.2 million for the same period last year. The resulting gross margin was 36.0%, compared with 75.0% for the same period last year.
Total Operating Expenses: For the three months ended March 31, 2022, total operating expenses were $3.9 million, an increase of $1.8 million, or 91%, compared with $2.0 million for the same period last year, as a direct result of professional fees and other accounting and legal fees related to the Company’s registration statement S-1 filing efforts.
Of note, $2.3 million of the Company's operating expenses for the three months ended March 31, 2022, were non-cash expenses, including depreciation, amortization, and stock-based compensation, compared to $0.5 million for the same period last year.

Operating Loss: For the three months ended March 31, 2022, operating loss was $3.2 million, an increase of $1.4 million, compared with an operating loss of $1.8 million for the same period last year.
Adjusted EBITDA Loss: For the three months ended March 31, 2022, Adjusted EBITDA loss was $0.9 million, a decrease of $0.4 million, or 30%, compared with an Adjusted EBITDA loss of $1.3 million for the same period last year, after deducting non-cash and one-time expenses.
Net Loss: For the three months ended March 31, 2022, net loss was $3.5 million, an increase of $1.3 million, or 60%, compared with $2.2 million for the same period last year. The EPS loss per share for the three months ended March 31, 2022, was ($1.10), compared to ($3.58) for the same period last year.
About Can B Corp.

Can B Corp. (OTCQB: CANB) is a health & wellness company providing the highest quality hemp-derived cannabinoid products, including under its own brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil, and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B Corp. operates R&D and production facilities in Lacey, WA, and Florida. To learn more about Can B Corp. and our comprehensive line of high-quality products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: CanBCorp.com

Twitter @CanBCorp

Instagram @canbcorp

Facebook @ Can B Corp

YouTube

[Penny Masters]

Not sure how much longer they will be around as they are bleeding money, massive debt, bloated salaries and CBD products that are overstocked falling off the shelves or expiring.

Peace out

[waterchaser]

It just got 17% worse today.

Can this charade get any worse?

[waterchaser]

Can this charade get any worse?

[Penny Masters]

Amazing CANB is still trading. After multi RS's, massive debt and products that no one wants. Simply a matter of time till the house of cards falls.

Peace out

[Penny Masters]

CANB always was a cesspool stock. Make sense and each RS was a knife in the back of share holders.

Peace out

[waterchaser]

CANB swirling the toilet.

[Penny Masters]

Everyone ever in CANB was forced long from multi RS's. The true value of CANB now is trips. No way out and best to offset and sell it when you have other gains.

What a mess and surprised they are still trading.


Peace out

[CHnJUP]

For the record I'm long. BUT.
yesterday they run to 3.70 and then sell off in the EOD....seems kind fishy. I wish they would figure this shit out. The company is making money we just need a good story for the market.
GLTA

[badguy3101]

It will never change too! CANB = NASDAQ




The Badguy

[waterchaser]

CANB up zero-percent today, not 20%.
Big dump at 3:54pm.
$3.00 represents what in pre-split value?
Low trip zeros?

[skyhawk66]

CANB Up almost 20% Today…Again.
Clearly Accumulation Continues.
Congratulations to Smart Money for Loading up on Shares in this Discounted Range.

Nasdaq Cometh

Patience and Vision will pay off Heavily

[skyhawk66]

Correct, CANB Going to Nasdaq.

Your Stable Vision will remain.

Mark It.

[waterchaser]

CANB = Dead Money.

[badguy3101]

CANB=NASDAQ

Vision




The Badguy

[waterchaser]

No worries, CANB will NEVER be on the NASDAQ,
Your stable voice will remain.

[Penny Masters]

CANB "NEVER EVER" going to NASDAQ! Mark it.

I will never ever post again on IHub if CANB goes to NASDAQ. Mark that too.

Peace out

[badguy3101]

The real action will begin on NASDAQ

OTC land = impulsive Rookies

NASDAQ = PROS and BIG institutional money/traders!!!

Day to day action down here doesn't mean shit to me. NASDAQ is the prize!

CANB = NASDAQ



The Badguy

[waterchaser]

$3.00 represents what in pre-split value?
Low trip zeros?

[skyhawk66]

CANB UP almost 28% Today, As Accumulation Continues. Only A Total Fool would still falsely say going out of business 4 years later.

Nasdaq Cometh, Easy to see why:

THE HIGHEST QUARTERLY REVENUE IN COMPANY HISTORY, Very Impressive Indeed:

Can B Corp. Reports First Quarter Revenue Growth of 606% to $1.9 Million, the Highest Quarterly Revenue in Company History
May 18 2022 - 07:26AM

Strengthened Balance Sheet with Increases to $17.0 Million in Total Assets and $6.2 Million in Stockholders Equity

HICKSVILLE, NY -- May 18, 2022 -- InvestorsHub NewsWire -- Can B Corp. (OTCQB: CANB) (“Can B'' or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company's financial results for the first quarter ended March 31, 2022.

Key Financial Highlights for Q1 2022

Revenue increased 606% to $1.9 million
Gross profit increased 291% to $0.7 million
Adjusted EBITDA loss decreased 30% to $0.9 million
Total assets increased to $17.0 million
Total stockholders’ equity increased to $6.2 million
Key Business Highlights for Q1 2022

Solidified and integrated vertical processing capabilities from recent acquisitions
Advanced build-out of first CBD lounge in Miami, Florida
Continuing path for potential NASDAQ up-listing
Management Commentary

Marco Alfonsi, Can B’s Chief Executive Officer, stated, “We are extremely pleased with our tremendous quarterly results, having achieved the highest quarterly revenue in our company history. We generated the $1.9 million in quarterly revenue while reducing our cash burn as demonstrated by the decrease in adjusted EBITDA to $0.9 million. The strategic moves we have made over the past several months have completed our vertical processing capabilities and put us in great position to accelerate our revenue growth and strengthen our balance sheet. This quarter’s results prove our plans are working as our team continues its hard at work integrating and ramping up the various operations to continue this momentum into the future.”

Alfonsi concluded, “Can B is now a full-service hemp-derived cannabinoid company that can facilitate servicing the large box types as well as the boutique vape and smoke store. Our dramatic revenue improvements, coupled with our acquisitions and asset base increases, position us solidly to continue our application process for a NASDAQ up listing.”

Vertical Processing Capabilities

Secured hemp biomass and winterized crude to create over 13,000 Liters (1 Liter = 1.05 Quarts) of isomers, including Delta-8, with a potential wholesale value exceeding $10 million at today's market price. Can B's late 2021 acquired facilities in Colorado will receive harvested hemp biomass and convert it to winterized crude. These same facilities will then process it to distillate, then to isolate which will be shipped to Company-owned facilities in Florida and Tennessee to produce Delta-8 or other isomers, or to its manufacturing facility in Lacey, Washington for its line of CBD tinctures, salves, gels, and drops. This processing is expected to take 5-6 months to produce 13,000 liters of Delta-8 and other isomers with potential revenue of $10 million.

300,000 Square Foot Facility in McMinnville, Tennessee
Acquisition of Assets from TWS Pharma included leases on a total of 15,000 square foot of facilities located in Mead and Ft. Morgan Colorado.
Acquisition of Assets from Music City Botanicals added additional volume in extraction, isomer lab production, and R&D into the evolving isomer market with such products as Delta-10, CBG, CBN, and CBDA.
Financial Results for the Three Months Ended March 31, 2022:

Revenue: For the three months ended March 31, 2022, revenue was $1.9 million, an increase of $1.6 million, or 606%, compared with $0.3 million for the same period last year. The increase is due to the wind-down of restrictions related to the Covid-19 Pandemic surrounding elective surgeries, enabling an increase in the usage of the Company’s Duramed product lines and ultrasound device associated with patient recovery. Additionally, due to asset acquisitions in 2021, the Company’s Music City Botanical and Botanical Biotech brands related to an increase in sales compared to 2021 of $0.6 million.
Gross Profit: For the three months ended March 31, 2022, gross profit was $0.7 million, an increase of $0.4 million, or 291%, compared with $0.2 million for the same period last year. The resulting gross margin was 36.0%, compared with 75.0% for the same period last year.
Total Operating Expenses: For the three months ended March 31, 2022, total operating expenses were $3.9 million, an increase of $1.8 million, or 91%, compared with $2.0 million for the same period last year, as a direct result of professional fees and other accounting and legal fees related to the Company’s registration statement S-1 filing efforts.
Of note, $2.3 million of the Company's operating expenses for the three months ended March 31, 2022, were non-cash expenses, including depreciation, amortization, and stock-based compensation, compared to $0.5 million for the same period last year.

Operating Loss: For the three months ended March 31, 2022, operating loss was $3.2 million, an increase of $1.4 million, compared with an operating loss of $1.8 million for the same period last year.
Adjusted EBITDA Loss: For the three months ended March 31, 2022, Adjusted EBITDA loss was $0.9 million, a decrease of $0.4 million, or 30%, compared with an Adjusted EBITDA loss of $1.3 million for the same period last year, after deducting non-cash and one-time expenses.
Net Loss: For the three months ended March 31, 2022, net loss was $3.5 million, an increase of $1.3 million, or 60%, compared with $2.2 million for the same period last year. The EPS loss per share for the three months ended March 31, 2022, was ($1.10), compared to ($3.58) for the same period last year.
About Can B Corp.

Can B Corp. (OTCQB: CANB) is a health & wellness company providing the highest quality hemp-derived cannabinoid products, including under its own brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil, and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B Corp. operates R&D and production facilities in Lacey, WA, and Florida. To learn more about Can B Corp. and our comprehensive line of high-quality products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: CanBCorp.com

Twitter @CanBCorp

Instagram @canbcorp

Facebook @ Can B Corp

YouTube

[Penny Masters]

After CANB broke 3.00 it was game over. CANB has nothing left and surprised they did not announce sector change already.

peace out